XML 66 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900
Business Combinations (Fiscal Year 2013 Narrative) (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2014
USD ($)
Oct. 31, 2013
USD ($)
Aug. 31, 2013
CHF (SFr)
Aug. 31, 2013
USD ($)
Jul. 31, 2013
USD ($)
Jun. 30, 2013
USD ($)
Mar. 30, 2013
USD ($)
Jan. 02, 2016
USD ($)
Jan. 03, 2015
USD ($)
Dec. 28, 2013
USD ($)
Aug. 31, 2013
USD ($)
Jan. 01, 2011
USD ($)
Business Acquisition [Line Items]                        
Business combination payments, net of cash acquired               $ 3,252,000,000 $ 147,000,000 $ 292,000,000    
Spinal Modulation [Member]                        
Business Acquisition [Line Items]                        
Business combination payments, net of cash acquired           $ 0            
Contingent consideration           0            
Total consideration           $ 124,000,000            
Voting equity interest           19.00%            
Remeasured fair value           $ 0            
Acquisition of controlling ownership interest           40,000,000            
Debt financing           0            
CardioMEMS, Inc [Member]                        
Business Acquisition [Line Items]                        
Business combination payments, net of cash acquired             $ 0          
Contingent consideration             0          
Total consideration             143,000,000          
Voting equity interest                       19.00%
Remeasured fair value             31,000,000          
Acquisition of controlling ownership interest             0         $ 60,000,000
Additional payment for acquisition                       $ 375,000,000
Debt financing         $ 9,000,000   28,000,000          
Remeasurement loss             29,000,000          
Developed Technology Rights [Member] | Spinal Modulation [Member]                        
Business Acquisition [Line Items]                        
Intangible assets           $ 7,000,000            
Weighted average useful life           12 years            
In Process Research and Development [Member] | Spinal Modulation [Member]                        
Business Acquisition [Line Items]                        
Indefinite-lived intangible assets           $ 45,000,000            
In Process Research and Development [Member] | CardioMEMS, Inc [Member]                        
Business Acquisition [Line Items]                        
Indefinite-lived intangible assets             $ 63,000,000          
Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member]                        
Business Acquisition [Line Items]                        
Payment of contingent consideration                 155,000,000      
Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Spinal Modulation [Member]                        
Business Acquisition [Line Items]                        
Payment of contingent consideration                 0      
Endosense S.A. [Member]                        
Business Acquisition [Line Items]                        
Business combination payments, net of cash acquired     SFr 160,000,000 $ 171,000,000                
Additional cash payment | SFr     SFr 150,000,000                  
Contingent consideration                     $ 132,000,000  
Total consideration                     303,000,000  
Reclassification of acquired in process research and development from indefinite-lived to definite-lived       33,000,000                
Remeasured fair value       0                
Acquisition of controlling ownership interest                     0  
Debt financing       $ 0                
Endosense S.A. [Member] | Developed Technology Rights [Member]                        
Business Acquisition [Line Items]                        
Intangible assets                     20,000,000  
Weighted average useful life     7 years 7 years                
Endosense S.A. [Member] | In Process Research and Development [Member]                        
Business Acquisition [Line Items]                        
Indefinite-lived intangible assets                     $ 33,000,000  
Endosense S.A. [Member] | Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member]                        
Business Acquisition [Line Items]                        
Payment of contingent consideration $ 155,000,000               155,000,000      
Nanostim [Member]                        
Business Acquisition [Line Items]                        
Business combination payments, net of cash acquired   $ 121,000,000                    
Additional cash payment   65,000,000                    
Contingent consideration   56,000,000                    
Total consideration   $ 210,000,000                    
Voting equity interest   18.00%                    
Remeasured fair value   $ 33,000,000                    
Acquisition of controlling ownership interest   0                    
Debt financing   0                    
Nanostim [Member] | Developed Technology Rights [Member]                        
Business Acquisition [Line Items]                        
Intangible assets   $ 34,000,000                    
Weighted average useful life   10 years                    
Nanostim [Member] | In Process Research and Development [Member]                        
Business Acquisition [Line Items]                        
Indefinite-lived intangible assets   $ 27,000,000                    
Nanostim [Member] | Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member]                        
Business Acquisition [Line Items]                        
Payment of contingent consideration                 $ 0      
Spinal Modulation [Member] | In Process Research and Development [Member]                        
Business Acquisition [Line Items]                        
Indefinite-lived intangible assets           $ 45,000,000